financetom
Business
financetom
/
Business
/
Intuit Beats First-Quarter Sales Views on QuickBooks, Credit Karma Gains
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intuit Beats First-Quarter Sales Views on QuickBooks, Credit Karma Gains
Nov 21, 2024 6:54 PM

04:37 PM EST, 11/21/2024 (MT Newswires) -- Intuit (INTU) late Thursday reported stronger-than-expected fiscal first-quarter revenue, buoyed by gains in the financial technology platform's QuickBooks and Credit Karma offerings.

Revenue increased 10% year-over-year to $3.28 billion during the three months ended Oct. 31, above the consensus compiled by FactSet of $3.14 billion. Adjusted per-share earnings rose to $2.50 from $2.47.

The global business solutions group's revenue increased 9% to $2.5 billion, buoyed by a 21% rise in QuickBooks online accounting sales that reflected customer growth and higher prices, Intuit said.

Personal finance portal Credit Karma's revenue climbed 29% to $524 million, driven by personal loans, auto insurance and credit cards. The consumer group's sales declined 6% to $176 million.

The parent of tax-preparation software TurboTax affirmed its fiscal 2025 guidance. Adjusted EPS is seen growing 13% to 14% annually, reaching $19.16 to $19.36. Revenue is projected to rise 12% to 13%, totaling $18.16 billion to $18.35 billion. The consensus estimate is for sales of $18.27 billion.

For the second quarter ending Jan. 31, Intuit projected adjusted EPS of $2.55 to $2.61 and revenue between $3.81 billion and $3.85 billion. Analysts polled by FactSet are looking for $3.89 billion.

Shares were down 5.6% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Salesforce Insider Sold Shares Worth $7,386,863, According to a Recent SEC Filing
Salesforce Insider Sold Shares Worth $7,386,863, According to a Recent SEC Filing
Apr 2, 2024
04:23 PM EDT, 04/02/2024 (MT Newswires) -- Brian Millham, President and COO, on April 01, 2024, sold 24,453 shares in Salesforce ( CRM ) for $7,386,863. SEC Filing: https://www.sec.gov/Archives/edgar/data/1108524/000112760224011829/xslF345X03/form4.xml Price: 303.74, Change: -0.26, Percent Change: -0.09 ...
Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing
Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing
Apr 2, 2024
04:21 PM EDT, 04/02/2024 (MT Newswires) -- Shelley B Thunen, Chief Financial Officer, on April 01, 2024, sold 20,000 shares in Rxsight ( RXST ) for $997,946. Following the Form 4 filing with the SEC, Thunen has control over a total of 22,093 shares of the company, with 13,691 shares held directly and 8,402 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1111485/000095017024040174/xslF345X03/ownership.xml Price:...
Salesforce Insider Sold Shares Worth $4,525,774, According to a Recent SEC Filing
Salesforce Insider Sold Shares Worth $4,525,774, According to a Recent SEC Filing
Apr 2, 2024
04:19 PM EDT, 04/02/2024 (MT Newswires) -- Marc Benioff, Director, Chair and CEO, on April 01, 2024, sold 15,000 shares in Salesforce ( CRM ) for $4,525,774. Following the Form 4 filing with the SEC, Benioff has control over a total of 23,011,166 shares of the company, with 13,011,166 shares held directly and 10,000,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1108524/000112760224011826/xslF345X03/form4.xml ...
IceCure Medical Seeks FDA Clearance for Cryoablation Technology
IceCure Medical Seeks FDA Clearance for Cryoablation Technology
Apr 2, 2024
04:24 PM EDT, 04/02/2024 (MT Newswires) -- IceCure Medical ( ICCM ) said Tuesday it filed an application with the US Food and Drug Administration for clearance of XSense, a single probe cryoablation technology. The 501(k) submission for XSense covers all indications for which ProSense, an early iteration of the technology, is already approved, according to the company. IceCure said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved